• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Topics » BioWorld, Analysis and data insight

BioWorld, Analysis and data insight
BioWorld, Analysis and data insight RSS Feed RSS

Money raised by biopharma: 2020 vs. 2019

Feb. 21, 2020
Total raised in public, private and other financings of biopharma companies, comparing 2020 vs. 2019.
Read More

Biopharma money raised: Jan. 1-Feb. 20, 2020

Feb. 21, 2020
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More

Biopharmaceutical collaborations: January 2020

Feb. 21, 2020
Biopharma licensings, joint ventures and collaborations, including: 4SC, Abbvie, Amgen, Aska, Astellas, Astrazeneca, Bayer, Biogen, Biomed X, Boehringer, Chiesi Farmaceutici, Clinigen, Curis, Cyclica, Daewoong, Daiichi Sankyo, Evotec, Gilead, Hikma, Innovent, Inovio, Ionis, Iovance, Janssen, Mediwound, Merck & Co., Merck KGaA, Mundipharma, Nestle, Novartis, Novo Nordisk, Pfizer, Pharmamar, Phasebio, Probiogen, Roche, Schrodinger, Syndivia, Takeda.
Read More

Biggest gainers and losers for the week of Feb. 17-21, 2020

Feb. 21, 2020
The top 10 biopharma stock gainers and losers for the week.
Read More
Cancer cell destruction by nanoparticles
Over the speed bump

Biopharmas developing cancer drugs whipsaw into 2020

Feb. 18, 2020
By Peter Winter
The BioWorld Cancer index, which includes 21 representative companies developing therapies targeting various cancers, entered the new year on a high note, after posting a 22.5% gain for the year. Unfortunately, the group hit a speed bump and the index took a beating in January, dropping almost 9% as a result.
Read More

Week in review for Feb. 10-14, 2020: Candidate therapies hit speed bumps

Feb. 18, 2020
By Peter Winter
A quick look back at top stories, including: Advaxis, Avrobio, Beam, Biohaven, Blue Water, CNS, Collegium, Cortexyme, Deciphera, Eli Lilly, Genprex, Gibson, I-Mab, Inato, Logicbio, Moderna, Personalis, Promedior, Revance, Revolution, Roche, Syros, Theravance, Xeris, WPD.
Read More

Money raised by biopharma: 2020 vs. 2019

Feb. 14, 2020
Total raised in public, private and other financings of biopharma companies, comparing 2020 vs. 2019.
Read More

Biopharma money raised: Jan. 1-Feb. 13, 2020

Feb. 14, 2020
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More

Regulatory submissions, approvals and other actions: January 2020

Feb. 14, 2020
Regulatory decisions affecting biopharma products in development, including: Abbvie, Aimmune, Alkermes, Alnylam, Amarin, Biohaven, Biolinerx, Blueberry, Clovis, Cytodyn, Durect, Emergent, Evoke, Exelixis, Fate, F-star, Galapagos, Genmab, Horizon, Incyte, Ipsen, Janssen, Jubilant, Mesoblast, Nabriva, Nektar, Nicox, Orion, Pharmacyte, Pharming, Pulmatrix, Recordati, Regeneron, Seelos, Sorrento, Ultragenyx, Vistagen.
Read More

Biggest gainers and losers for the week of Feb. 10-14, 2020

Feb. 14, 2020
The top 10 biopharma stock gainers and losers for the week.
Read More
Previous 1 2 … 177 178 179 180 181 182 183 184 185 … 201 202 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 23, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 24, 2025
  • Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

    Otsuka licenses Harbour’s bispecific T-cell engager for $670M

    BioWorld
    Harbour Biomed is out-licensing its B-cell maturation antigen and CD3 bispecific T-cell engager HBM-7020 for autoimmune diseases to Otsuka Pharmaceutical Co. Ltd....
  • Scientists shaking hands in the lab

    Illumina buying Somalogic for up to $425M to boost multiomics assets

    BioWorld MedTech
    In a bid to boost its multiomics holdings, Illumina Inc. reported an agreement to buy proteomics technology company Somalogic Inc. from Standard Biotools Inc. for...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe